Medication info

Bandron Injection (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Jinyang Pharmaceutical Co., Ltd.
Appearance
An injection solution that is a colorless, transparent liquid contained in a colorless, transparent glass prefilled syringe, with a single-use needle attached.
Packaging
1 vial of 3mL
Approval status
Active

MFDS item code 201309479 · Approved 2013.09.27 · Insurance code 650303071

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, and then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Administration of this drug is not recommended in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, as clinical experience in these patients is insufficient. Elderly patients No dose adjustment is necessary.
Child administration
Efficacy and safety have not been studied in children 18 years of age or younger.

Ingredients

Manufacturer
Jinyang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis that may occur in postmenopausal women. Osteoporosis is a condition where bones become weak and fracture easily, particularly common in women after menopause. This drug helps to increase bone density and improve bone health, thereby reducing the risk of fractures. By treating osteoporosis, it helps to reduce bone damage and pain in daily life and maintain a healthy lifestyle. Therefore, it is effectively used for the treatment of osteoporosis in postmenopausal women.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, and then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Administration of this drug is not recommended in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, as clinical experience in these patients is insufficient. Elderly patients No dose adjustment is necessary.

Child administration

Efficacy and safety have not been studied in children 18 years of age or younger.

Precautions

This medication must be administered intravenously and caution is required as administering into the arteries or perivascular areas may cause tissue damage. Patients with hypersensitivity to this medication or its ingredients and those with untreated hypocalcemia should not be administered this drug. Some patients may experience gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation during the use of this medication. Musculoskeletal side effects may include muscle pain, joint pain, and musculoskeletal pain, while systemic side effects may include influenza-like symptoms and fatigue. Neurological and skin reactions such as headaches and rashes have also been reported. Rarely, serious allergic reactions such as anaphylaxis may occur during administration of this medication, requiring immediate medical attention. This medication can temporarily lower serum calcium levels; therefore, hypocalcemia and disorders of bone and mineral metabolism should be treated before administration, and it is important to ensure sufficient intake of calcium and vitamin D. For patients undergoing dental treatment or with poor oral hygiene, there is a risk of jaw osteonecrosis, so it is advisable to have an oral examination before administration. During the administration of this medication, excessive dental procedures should be avoided, as surgical procedures in the case of jaw osteonecrosis may worsen the condition. Additionally, bisphosphonates, including this medication, have been reported to be associated with bone-related abnormalities such as osteonecrosis of the external auditory canal and atypical femoral fractures, so immediate evaluation is necessary if pain is experienced in the thigh or groin. This medication is not metabolized in the liver and is mainly excreted through the kidneys, so patients with impaired kidney function require regular monitoring. It is recommended that women who are pregnant or breastfeeding do not use this medication, and the safety and efficacy in patients under 18 years of age have not been established. Overdosage may lead to toxicity in the kidneys and liver, necessitating careful monitoring and appropriate treatment if symptoms such as hypocalcemia occur. This medication should not be mixed with calcium-containing solutions or other intravenous drugs and must be administered as an intravenous injection only. Used injection needles and syringes should not be reused and should be disposed of safely.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling/edema, urticaria, osteonecrosis of the jaw and external ear, uveitis, episcleritis, scleritis, anaphylactic reaction/shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral shaft and intertrochanteric fracture, dizziness, optic atrophy, lower motor neuron lesions, tremor, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin peeling, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent contact with air, at room temperature between 1 and 30 degrees Celsius. Therefore, it is important to avoid extremely hot or cold places and store it in an area that maintains an appropriate temperature.

Appearance and packaging

Appearance

An injection solution that is a colorless, transparent liquid contained in a colorless, transparent glass prefilled syringe, with a single-use needle attached.

Package unit

1 vial of 3mL

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.